Literature DB >> 20069333

CK20 and Ki-67 as significant prognostic factors in human bladder carcinoma.

Yong-kang Ye1, Xue-cheng Bi, Hui-chan He, Zhao-dong Han, Qi-shan Dai, Yu-xiang Liang, Guo-hua Zeng, Wei-jun Qin, Zhi-nan Chen, Wei-de Zhong.   

Abstract

Aberrant expression of CK20 and Ki-67 has been documented in many kinds of primary tumors and has proved useful as an ancillary diagnostic aid for those tumors. The aim of this study was to analyze the expression patterns of CK20 and Ki-67 in human bladder carcinomas (BCa) and to evaluate their clinical significance in the progression of BCa. CK20 and Ki-67 expression in BCa and normal bladder tissues were detected by immunohistochemical staining. The Spearman correlation was calculated between the expression of CK20 and Ki-67 in BCa tissues. The correlation of CK20 and Ki-67 expression with the clinicopathological characteristics and the prognosis of BCa were subsequently assessed. CK20 expression was positively expressed in 103/154 (66.9%) of BCa and 2/30 (6.67%) of normal bladder tissues, respectively. The positive expression rate of Ki-67 in BCa tissues was also significantly higher than those in normal bladder tissues (81.8 vs. 10%, p < 0.01). The Spearman analysis indicated that the expression level of CK20 has a significant positive correlation with that of Ki-67 (rs = 0.86, p = 0.02). Pathologic findings demonstrated that the intensity of CK20 and Ki-67 staining in cancerous tissues was associated significantly with tumor grades (p = 0.03, p < 0.01), distant metastasis (both p < 0.01) and TNM grades (p = 0.01, p = 0.03) of BCa. The progression-free survival of the patients with CK20 (+)/Ki-67 (+) expression was poorest (p < 0.01). The results suggest that the expression of CK20 and Ki-67 may be an important feature of BCa, and the detection of their co-expression may benefit the prediction of BCa prognosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20069333     DOI: 10.1007/s10238-009-0088-3

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  28 in total

1.  Expression of cytokeratin 20 redefines urothelial papillomas of the bladder.

Authors:  P Harnden; N Mahmood; J Southgate
Journal:  Lancet       Date:  1999-03-20       Impact factor: 79.321

2.  Immunohistochemical evaluation of PCNA and Ki-67 in ameloblastoma.

Authors:  F Sandra; T Mitsuyasu; N Nakamura; Y Shiratsuchi; M Ohishi
Journal:  Oral Oncol       Date:  2001-02       Impact factor: 5.337

3.  Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation.

Authors:  J Gerdes; U Schwab; H Lemke; H Stein
Journal:  Int J Cancer       Date:  1983-01-15       Impact factor: 7.396

4.  Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity.

Authors:  E Kavaler; J Landman; Y Chang; M J Droller; B C Liu
Journal:  Cancer       Date:  1998-02-15       Impact factor: 6.860

5.  Cytokeratin 7 and 20 expression in cholangiocarcinomas varies along the biliary tract but still differs from that in colorectal carcinoma metastasis.

Authors:  A Rullier; B Le Bail; R Fawaz; J F Blanc; J Saric; P Bioulac-Sage
Journal:  Am J Surg Pathol       Date:  2000-06       Impact factor: 6.394

6.  Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases.

Authors:  P Chu; E Wu; L M Weiss
Journal:  Mod Pathol       Date:  2000-09       Impact factor: 7.842

7.  Expression of COX-2, PCNA, Ki-67 and p53 in gastrointestinal stromal tumors and its relationship with histopathological parameters.

Authors:  Derya Gumurdulu; Seyda Erdogan; Fazilet Kayaselcuk; Gulsah Seydaoglu; Cem-K Parsak; Orhan Demircan; Ilhan Tuncer
Journal:  World J Gastroenterol       Date:  2007-01-21       Impact factor: 5.742

8.  Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder?

Authors:  Paul Sweeney; Randall Millikan; Machelle Donat; Christopher G Wood; Arlene Siefker Radtke; Curtis A Pettaway; H Barton Grossman; Colin P N Dinney; David A Swanson; Louis L Pisters
Journal:  J Urol       Date:  2003-06       Impact factor: 7.450

9.  Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer.

Authors:  M F Sarosdy; R W deVere White; M S Soloway; J Sheinfeld; M A Hudson; P F Schellhammer; M V Jarowenko; G Adams; B A Blumenstein
Journal:  J Urol       Date:  1995-08       Impact factor: 7.450

10.  Low grade transitional cell carcinoma of the bladder. Cytologic diagnosis by key features as identified by logistic regression analysis.

Authors:  S S Raab; J C Lenel; M B Cohen
Journal:  Cancer       Date:  1994-09-01       Impact factor: 6.860

View more
  7 in total

1.  [Personalized urooncology based on molecular uropathology: part 1: what is diagnostic routine?].

Authors:  C G Stöhr; R Stöhr; A Rogler; K Amann; R Knüchel-Clarke; A Hartmann
Journal:  Urologe A       Date:  2013-07       Impact factor: 0.639

Review 2.  [Urine cytology - update 2013. A systematic review of recent literature].

Authors:  M Böhm; F vom Dorp; M Schostak; O W Hakenberg
Journal:  Urologe A       Date:  2013-09       Impact factor: 0.639

3.  Adenylate kinase 4 promotes bladder cancer cell proliferation and invasion.

Authors:  Feng Xin; Dong-Wei Yao; Li Fan; Jiu-Hua Liu; Xiao-Dong Liu
Journal:  Clin Exp Med       Date:  2019-08-28       Impact factor: 3.984

4.  Altered expression of CKs 14/20 is an early event in a rat model of multistep bladder carcinogenesis.

Authors:  Rui M Gil da Costa; Paula A Oliveira; Carmen Vasconcelos-Nóbrega; Regina Arantes-Rodrigues; Rosário Pinto-Leite; Aura A Colaço; Luis F de la Cruz; Carlos Lopes
Journal:  Int J Exp Pathol       Date:  2015-10-30       Impact factor: 1.925

5.  FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.

Authors:  Lucie C Kompier; Irene Lurkin; Madelon N M van der Aa; Bas W G van Rhijn; Theo H van der Kwast; Ellen C Zwarthoff
Journal:  PLoS One       Date:  2010-11-03       Impact factor: 3.240

6.  Immunohistochemistry and Fluorescence In Situ Hybridization Can Inform the Differential Diagnosis of Low-Grade Noninvasive Urothelial Carcinoma with an Inverted Growth Pattern and Inverted Urothelial Papilloma.

Authors:  Juan-Juan Sun; Yong Wu; Yong-Ming Lu; Hui-Zhi Zhang; Tao Wang; Xiao-Qun Yang; Meng-Hong Sun; Chao-Fu Wang
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

7.  Comprehensive Analysis of the Effects of Genetic Ancestry and Genetic Characteristics on the Clinical Evolution of Oral Squamous Cell Carcinoma.

Authors:  Junfeng Guo; Xiaoping Liu; Yi Zeng; Taotao Liang; Kanglai Tang; Junfeng Guo; Weiwei Zheng
Journal:  Front Cell Dev Biol       Date:  2021-12-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.